Conference Reports for NATAP

Back

20th International AIDS Conference July 20-25, 2014 Melbourne, Australia     HIV Prevention at AIDS 2014 - PrEP, TasP, PMTCT, Key Populations - Jared Baeten, MD PhD Kenneth Ngure, PhD, MPH Connie Celum, MD MPH University of Washington & Jomo Kenyatta University of Agriculture and Technology - (07/31/14)   HIV Cure Reports, "Towards a Cure" Symposium at IAC - (08/21/14)   IAS pre-meeting "Towards a Cure" Symposium - written by David Margolis MD, UNC Chapel Hill - (08/21/14)   HCV at IAC/2014-Melbourne - (08/22/14)   Aging, Comorbidities - Inflammation/Activation-Gut, Complications - Bone, Neuro/Brain, Kidney, Heart Disease, HPV, Pnuemococcal disease - Adherence, Tolerability/Adverse Events (50 reports) - (08/22/14)   Incidence and risk factors of HIV-infection among young men who have sex with men in Bangkok, Thailand - (08/13/14)   Pharmacokinetics of VM-1500 20 mg and 40 mg in Healthy and HIV-Infected Patients - (08/13/14)   ART in Acute Infection Quells Inflammation But Does Not Restore Gut CD4s - (08/11/14)   Antifibrotic activity of dual CCR5/CCR2 antagonist cenicriviroc in a mouse model of renal fibrosis - (08/08/14)   The HCV Care "Cliff": High burden of HCV disease and poor access to HCV services among people who inject drugs in India - (08/06/14)   FUNCTIONAL CURE AND SEROREVERSION AFTER ADVANCED HIV DISEASE FOLLOWING 7 YEARS OF ANTIRETROVIRAL TREATMENT INTERRUPTION - (08/06/14)   Probiotic and IL-21 Treatment Promotes Th17 Cell Recovery in ARV-Treatment of Pigtail Macaques - (08/06/14)   HIV-Exposed Seronegative Men who have Sex with Men overexpress potential antiviral antiproteases in their rectal mucosa - (08/06/14)   Open label, randomized, crossover, single-dose, bioavailability evaluation of atazanavir/ritonavir FDC tablets 300 mg/100 mg with that of REYATAZ 300 mg and NORVIR 100 mg under fed and fasting conditions - (08/05/14)   Body mass index (BMI) and change in levels of immune activation post- ART initiation in diverse low- and middle-income settings - (08/05/14)   About 40% Who Get Under 50 Copies Have Residual Viremia in French Cohort - Mark Mascolini - (08/04/14)   Recent HIV Testing among U.S. Older Adults Since and Prior to Release of CDC's Routine HIV Testing Recommendations: National Findings based on the Behavioral Risk Factor Surveillance System (BRFSS) - (08/04/14)   IAC Plenary on HIV/Aging & NATAP Reports on HIV/Aging-Complications / HCV /Activation / Inflammation/Kidney/Anal Cancer-HSIL clearance/COPD/Neuro-Cognitive Disorders - (08/04/14)   Does the Addition of HCV Testing to a Rapid HIV Testing Program Impact HIV Test Acceptance? A Randomized Controlled Trial - (08/04/14)   High Inflammation/Activation Markers Before and During ART Predict Death in MACS - Mark Mascolini - (08/04/14)   No HIV RNA or DNA, Negative Western Blot, After 7-Year ART Suspension - Mark Mascolini - (08/04/14)   Raltegravir May Offer Gut Microbe Advantages Compared With Nonnucleosides - Mark Mascolini - (08/04/14)   Health Workers Not Following CDC Advice on Testing Older Adults for HIV - Mark Mascolini - (08/04/14)   Sex on PrEP (08/04/14)   The burden of subclinical heart and lung disease detected on thoracic CT scans of HIV-infected individuals on antiretroviral therapy (08/04/14)   Raltegravir Regimen More Durable, Atazanavir Less Durable, Than Single-Tablet Atripla - Mark Mascolini - (08/01/14)   The HIV Care Cascade ("Cascade") Measured Over Multiple Time Periods Varies by Time Period and Method (08/01/14)   HPV VACCINATION IN HIV+ ADOLESCENTS AND YOUNG ADULTS INDUCES STRONG HPV-SPECIFIC CELL-MEDIATED IMMUNE RESPONSES (08/01/14)   Effect of monthly calcidiol supplementation on secondary hyperparathyroidism and bone mineral density in HIV-infected patients with vitamin D deficiency (07/31/14)   Lack of Clinically Relevant Drug Interactions Between Elvitegravir plus Ritonavir Boosted-Atazanavir and Telaprevir (07/30/14)   Darunavir (DRV)/r-based Postexposure Prophylaxis (PEP) versus standard of care (SOC) - quality of life in patients receiving PEP in a randomized study (PEPDar) (07/30/14)   Economic Burden of Adverse Events Associated With HIV Antiretroviral Therapy in the United States (07/30/14)   Monocyte activation markers remain significantly elevated in virologically suppressed HIV+ individuals to a level equivalent to an additional 4 years of normal ageing (07/30/14)   Safety and Efficacy of the Integrase Inhibitor-Based Stribild Single-Tablet Regimen in HIV-Infected Adolescents Through 24 Weeks of Treatment (07/29/14)   Pharmacokinetics of Boosted-Elvitegravir in Combination with Rifabutin, Utilizing Twice Daily Administration of Cobicistat to Overcome Induction (07/29/14)   Romidepsin HDAC Inhibitor Stimulates HIV from Reservoirs in Hunt to Find HIV Cure (07/29/14)   Treatment with the histone deacetylase inhibitor Panobinostat markedly reduces chronic inflammation in HIV-infected patients (07/29/14)   Real-World Adherence among Patients Receiving Single versus Multiple Tablet Regimens for HIV-1 Infection, and Associations between Adherence and Viral Suppression: A Systematic Literature Review and Meta- Analysis (07/29/14)   Cost-Effectiveness of Single versus Multiple Tablet Regimens for Treatment of HIV-1 Infection in the US (07/29/14)   Do Single Tablet Regimens Translate into More Durable HIV Treatments? Evidence from the Canadian Observational Cohort (CANOC) (07/29/14)   Monthly Vitamin D May Improve Bone Density in People With HIV - Mark Mascolini (07/28/14)   Ole, Pre-Exposure Prohylaxis (PrEP) Initiative: Open Label Extension - "Adherence Has To Be Good, Not Perfect," Say MSM PrEP Study Researchers - (07/28/14)   Improvement of kidney function after anti HCV therapy in hepatitis C/HIV coinfection - (07/28/14)   Efficacy and Safety of Dolutegravir (DTG) in Hepatitis (HBV or HCV) Co-infected Patients: Results From the Phase 3 Program - (07/28/14)   Allogeneic bone marrow transplantation in two HIV-1 infected patients shows no detectable HIV-1 RNA or DNA, and a profound reduction in HIV-1 antibodies - (07/28/14)   Tenofovir(TFV), Emtricitabine(FTC), Intracellular Metabolite, and Endogenous Nucleotide (EN) Concentrations as a Function of Aging in HIV+ Subjects - (07/28/14)   SIV-infected rhesus macaques receiving suppressive cART have continued GI damage, inflammation, immune activation and persistent low-level viral replication within lymphoid tissuesÉ"Suggesting that HIV Cure strategies will need to address sources of residual inflammation/immune activation to be successful" - (07/28/14)   Efficacy and Safety of Dolutegravir Relative to Commonly-Used 3rd-Agents at 96 Weeks in Treatment-Naive HIV-1-Infected Patients: A Systematic Review and Network Meta-analysis - (07/28/14)   Measuring Patient Views of HIV Treatments: Comparing Dolutegravir With Darunavir/r in the FLAMINGO Study - (07/28/14)   Diminished Physical Function in Older HIV+ Adults Despite Successful Antiretroviral Therapy - (07/28/14)   Week 144 Renal Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) from Two Phase 3 Randomized Controlled Trials - (07/28/14)   Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) in HIV-Infected Patients with Mild to Moderate Renal Impairment - (07/28/14)   STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Maintains Non-Inferiority to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults through Week 96 with a Favorable Safety Profile for Abnormal Dreams and Dizziness - (07/28/14)   STRATEGY Studies (GS-115 and GS-121): Safety Analysis of Switching to STB from a RTV-Boosted PI or NNRTI Plus TVD Regimen - (07/28/14)   Obesity Doubles Chances of More Inflammation and Monocyte Activation With HIV - written by Mark Mascolini - (07/28/14)   Activation Marker Levels With Undetectable Viral Load Match Those of Uninfected People 4 Years Older - written by Mark Mascolini - (07/28/14)   Time to Viral Suppression With ART for Acute HIV in Pregnancy - written by Mark Mascolini - (07/28/14)   Pneumococcal Disease Rate Drops in HIV Group But Still Far Exceeds HIV-Negative Rate - written by Mark Mascolini - (07/28/14)   Gait Speed in Older HIV Group Not Fast Enough to Cross Street Safely - written by Mark Mascolini - (07/28/14)   SAPPHIRE-II Subgroup Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-experienced Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics - (07/25/14)   Low Frequency of Anemia in Phase 3 Trials of ABT-450/r/ABT-267 and ABT-333 With Ribavirin in Treatment-naïve (SAPPHIRE-I) and Treatment-experienced (SAPPHIRE-II) Patients - (07/25/14)   Neurocognitive Disorder Rates Differ by US vs Local Standards in Australian MSM - Mark Mascolini - (07/25/14)   No Detectable HIV RNA or DNA in 2 Bone Marrow Transplant Patients Still on ART - Mark Mascolini - (07/25/14)   Why Undiagnosed HIV and HIV Incidence Are Falling in SF MSM and Static in London MSM - Mark Mascolini - (07/25/14)   Resistance Mutations Persist in HIV DNA After 12 Years With Undetectable Viral Load - Mark Mascolini - (07/25/14)   Predictors of Neurocognitive Decline and Rebound in US CHARTER Group - Mark Mascolini - (07/25/14)   HARNESS study: ritonavir-boosted atazanavir (ATV/r)+raltegravir (RAL) switch study in virologically suppressed, HIV-1-infected patients - (07/25/14)   Comparing the incidence and identifying risk factors for nephrolithiasis among patients exposed to atazanavir, other PIs and PI-free regimens - (07/25/14)   Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis - (07/25/14)   SAPPHIRE-I Subpopulation Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-naïve Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics   - (07/25/14)   Longer ART, Better CD4 Gain Protect From Neurocognitive Decline in ACTG Analysis - written by Mark Mascolini - (07/25/14)   Incidence and clearance of anal high-grade squamous intraepithelial lesions (HSIL) in HIV positive and HIV negative homosexual men (07/25/14)   MODERN Study - Maraviroc (MVC) Once Daily With Darunavir/Ritonavir(DRV/r) Compared to Tenofovir/Emtricitabine (TDF/FTC) With DRV/r: 48-Week Results From MODERN - ViiV Press Release (07/24/14)   Anal Cancer Precursor More Common in HIV+ Than HIV- MSM; Clearance Rate High - written by Mark Mascolini - (07/24/14)   Inflammatory Cytokine/IL-10 Ratios Tied to Regional Brain Atrophy With HIV - written by Mark Mascolini - (07/24/14)   Efavirenz Not Tied to Neurocognitive Impairment in Large Single-Center Study - written by Mark Mascolini - (07/24/14)   Inflammation/Activation Markers Drop With ATV, DRV, RAL, But Not Completely - ACTG Study - written by Mark Mascolini - (07/23/14)   Higher One-Year Risk of CVD or Diabetes Per BMI Unit Gained on ART - written by Mark Mascolini - (07/23/14)   Early Data Show Good Adherence to Intermittent PrEP by MSM in French Trial - written by Mark Mascolini - (07/23/14)   COPD Rate 7% in Global HIV Cohort--Half With COPD Never Smoked - written by Mark Mascolini - (07/23/14)   Once-Daily Maraviroc Inferior to TDF/FTC in First-Line Regimens With Darunavir - written by Mark Mascolini - (07/23/14)   Effect of viral suppression below 20 copies of HIV-RNA /mL of plasma on virological outcome of treated HIV- infected patients - (07/23/14)   Failure Risk Similar With 20 to 50 Copies and Always Under 20 Copies - written by Mark Mascolini - (07/23/14)   Switching From First-Line ART When Suppressed Boosts Failure Chance - written by Mark Mascolini - (07/23/14)   Quadrivalent HPV Vaccine Elicits Antibody and Cell Responses in HIV+ Teens, Young Adults - written by Mark Mascolini - (07/23/14)   Good Response and Resistance Record in Naive and Experienced Starting Dolutegravir - written by Mark Mascolini - (07/23/14)   Successful ART Started Under Age 6 Months More Likely to Yield Negative Antibody Test - written by Mark Mascolini - (07/22/14)   Virologic Failure Predictors in SECOND-LINE Trial of Raltegravir vs NRTIs (07/22/14)   The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays (07/22/14)   DTG-Based Regimens Are Active in INI-Naive Patients With a History of NRTI Resistance (07/22/14)   Maraviroc (MVC) Once Daily With Darunavir/Ritonavir(DRV/r) Compared to Tenofovir/Emtricitabine (TDF/FTC) With DRV/r: 48-Week Results From MODERN (Study A4001095) (07/22/14)   cART in First Days of Life Limits Viral Reservoir Size in 4 Canadian Children - written by Mark Mascolini - (07/22/14)   TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-INFECTED WITH HEPATITIS C AND HIV-1 (07/21/14)   Abbvie 3D  Regimen in HCV Genotype 1-Infected Patients on Methadone or Buprenorphine (07/21/14)   High SVR12 With Sofosbuvir/Ribavirin in HCV/HIV-Coinfected: PHOTON-2 - written by Mark Mascolini - (07/21/14)   High Response Rates With Triple-DAA Regimen in People With HCV and HIV: Abbvie 3D - ABT-450/ritonavir, ombitasvir, and dasabuvir, with ribavirin - written by Mark Mascolini - (07/21/14)   SVR12 Rate 97% With 3 DAAs Plus Ribavirin in People on Opioid Replacement - written by Mark Mascolini - (07/21/14)   High SVR12 With Sofosbuvir/Ribavirin in HCV/HIV-Coinfected: PHOTON-2 - written by Mark Mascolini - (07/21/14)   All-Oral Therapy with Sofosbuvir Plus Ribavirin for the Treatment of HCV Genotype 1, 2,3 and 4 Infection in Patients Coinfected with HIV (PHOTON-2) (07/21/14)   Prenatal Exposure to Zidovudine and Risk for Ventricular Septal Defects and Congenital Heart Defects: Data From the Antiretroviral Pregnancy Registry (APR) (07/21/14)   Liver Markers Worse in Youth With Than Without HIV and Climb Over Time - Written by Mark Mascolini (07/21/14)   FIB-4 Predicts Major Liver Complications and Death in HCV+ People Starting ART (07/21/14)